Complete Clinical Response in Rectal Cancer After Neoadjuvant Therapy: Organ Preservation Strategies and the Role of Surgery
The traditional concept of rectal cancer management has changed significantly over the last few years. Although surgical resection is still the main pillar in the management of distal rectal cancer by proctectomy and total mesorectal excision (TME), organ preservation strategies have gained popularity. Neoadjuvant chemoradiation (nCRT) may result in significant tumor regression and may lead to complete pathological response in up to 42% of patients. In an attempt to avoid considerable morbidity and functional consequences of proctectomy and TME, selected patients that develop complete clinical response to neoadjuvant chemoradiation have been offered organ-preserving strategies including transanal local excision or even no immediate surgery and strict follow-up (watch and wait (WW)) with acceptable oncological outcomes and minimal functional consequences. Transanal local excisions may be an attractive organ-preserving strategy in this setting by providing definitive confirmation of complete primary tumor regression after nCRT. However, specific issues in tumor regression patterns, wound healing, postoperative function, and surveillance may constitute significant disadvantages of this approach over watch and wait.
KeywordsRectal cancer Organ preservation Watch and wait Local excision Neoadjuvant chemoradiation
Conflicts of Interest
The authors have no conflicts of interest to declare.
- 12.Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.CrossRefGoogle Scholar
- 16.Habr-Gama A, Sao Juliao GP, Gama-Rodrigues J, et al. Baseline T classification predicts early tumor regrowth after nonoperative management in distal rectal cancer after extended neoadjuvant chemoradiation and initial complete clinical response. Dis Colon Rectum. 2017;60:586–94.CrossRefGoogle Scholar
- 22.Gerard JP, Benezery K, Doyen J, et al. Aims of combined modality therapy in rectal cancer (M0). Recent results. Cancer Res. 2014;203:153–69.Google Scholar
- 23.Sun Myint A, Smith FM, Gollins S, et al. Dose escalation using contact x-ray brachytherapy after external beam radiotherapy as nonsurgical treatment option for rectal cancer: outcomes from a single-center experience. Int J Radiat Oncol Biol Phys. 2018;100(3):565–73.Google Scholar
- 26.Fu XL, Fang Z, Shu LH, et al. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. Oncotarget. 2017;8(21):34340–51.Google Scholar
- 39.Hupkens BJP, Maas M, Martens MH, et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response? Ann Surg Oncol. 2018;25(1):197–203.Google Scholar
- 67.van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–45.Google Scholar